Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych |

Communication of the President of the Office of 6 December 2022 on the EMA's ETF recommendation on the use of a bivalent adapted vaccine against Omicron BA.4/5 subvariants and original SARS-CoV-2 virus in primary vaccination.

06/12/2022
Communication of the President of the Office, of 25.11.2022, on the CHMP recommendation, of 10.11.2022, for the authorisation of the booster vaccine VidPrevtyn Beta for adults previously vaccinated with the vector or mRNA vaccine against COVID-19.

25/11/2022
Communication of the President of the Office of 20 October 2022 on the recommendation of the Committee for Medicinal Products for Human Use (CHMP) EMA on the use of COVID-19 Comirnaty and Spikevax vaccines in children aged 6 months and older.

20/10/2022
Communication of the President of the Office of 20 October 2022 on the recommendation of the EMA's Committee for Medicinal Products for Human Use (CHMP) to authorise the marketing of the second adapted bivalent vaccine Spikevax against...

20/10/2022
Communication of the President of the Office of 16 September 2022 on recommendation of the European Medicines Agency (EMA) to convert the existing conditional marketing authorisations of the vaccines Comirnaty and Spikevax into standard...

16/09/2022
Communication of the President of the Office of 13 September 2022 on the recommendation of the European Medicines Agency (EMA) for approval of a bivalent vaccine adapted against Omicron BA.4/5 subvariants and primary SARS-CoV-2 virus.

13/09/2022
Communication of the President of the Office of 6 September 2022 on the publication of a statement by ECDC and EMA on booster vaccination with the bivalent vaccine against COVID-19 variant Omicron.

06/09/2022